Követés
roisin adams
roisin adams
National Centre for Pharmacoeconomics
E-mail megerősítve itt: stjames.ie
Cím
Hivatkozott rá
Hivatkozott rá
Év
Incorporating data from various trial designs into a mixed treatment comparison model
S Schmitz, R Adams, C Walsh
Statistics in medicine 32 (17), 2935-2949, 2013
1182013
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian …
S Schmitz, R Adams, CD Walsh, M Barry, O FitzGerald
Annals of the rheumatic diseases 71 (2), 225-230, 2012
1142012
Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis
R Adams, C Walsh, D Veale, B Bresnihan, O FitzGerald, M Barry
Pharmacoeconomics 28, 477-487, 2010
702010
The expiry of Humira® market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures
E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ...
Frontiers in pharmacology 11, 591134, 2021
652021
The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis
S Schmitz, R Adams, C Walsh
BMC medical research methodology 12, 1-17, 2012
392012
Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D
E Fogarty, C Walsh, R Adams, C McGuigan, M Barry, N Tubridy
Multiple Sclerosis Journal 19 (9), 1190-1196, 2013
382013
Understanding the challenges and uncertainties of seroprevalence studies for SARS-CoV-2
D McConnell, C Hickey, N Bargary, L Trela-Larsen, C Walsh, M Barry, ...
International Journal of Environmental Research and Public Health 18 (9), 4640, 2021
312021
Identifying and revealing the importance of decision-making criteria for health technology assessment: a retrospective analysis of reimbursement recommendations in Ireland
S Schmitz, L McCullagh, R Adams, M Barry, C Walsh
Pharmacoeconomics 34, 925-937, 2016
312016
Sofosbuvir and simeprevir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation
D Issa, B Eghtesad, NN Zein, L Yerian, M Cruise, N Alkhouri, R Adams, ...
International journal of organ transplantation medicine 7 (1), 38, 2016
262016
Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma
A Schritz, N Aouali, A Fischer, C Dessenne, R Adams, G Berchem, ...
Neuro-Oncology Advances 3 (1), vdab052, 2021
212021
Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients
V Gimeno-Ballester, J Mar, A O’Leary, R Adams, R San Miguel
Expert Review of Gastroenterology & Hepatology 11 (1), 85-93, 2017
202017
Health-related quality of life of HIV-infected intravenous drug users
S Surah, R Adams, L Townsend, I Reynolds, JC Kinahan, S Keating, ...
International journal of STD & AIDS 24 (11), 867-874, 2013
202013
A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)
D Wall, N Meah, K York, B Bhoyrul, L Bokhari, LS Abraham, R Adams, ...
JAMA dermatology 157 (4), 439-448, 2021
152021
Evaluating the neonatal BCG vaccination programme in Ireland
C Usher, R Adams, S Schmitz, J Kieran, D O’Flanagan, J O’Donnell, ...
Archives of Public Health 74, 1-12, 2016
132016
Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements
HG Eichler, R Adams, E Andreassen, P Arlett, M Van de Casteele, ...
International Journal of Technology Assessment in Health Care 37 (1), e83, 2021
112021
The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort
R Adams, BM Craig, CD Walsh, DJ Veale, B Bresnihan, O FitzGerald, ...
Value in Health 14 (6), 921-927, 2011
92011
Using the analytic hierarchy process to derive health state utilities from ordinal preference data
BP Reddy, R Adams, C Walsh, M Barry, P Kind
Value in Health 18 (6), 841-845, 2015
82015
An evaluation of research replication and market segmentation with Q method
RC Adams
Operant Subjectivity 6 (4), 1983
71983
Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
S Spillane, C Usher, K Bennett, R Adams, M Barry
Journal of Pharmaceutical Policy and Practice 8 (sup1), O10, 2015
62015
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
D McConnell, M Harte, C Walsh, D Murphy, A Nichol, M Barry, R Adams
Scientific Reports 12 (1), 17561, 2022
52022
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20